Us Bancorp \De\ Chemo Centryx, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Oct 27, 2022	SELL	$22.17 - $51.8 $266 - $621	-12 Reduced 0.45%	2,681 $138,000
Q2 2022 Aug 01, 2022	SELL	$15.36 - $27.51 $11,243 - $20,137	-732 Reduced 21.37%	2,693 $66,000
Q1 2022 May 11, 2022	BUY	$22.22 - $39.12 $6,466 - $11,383	291 Added 9.29%	3,425 $86,000
Q4 2021 Feb 11, 2022	BUY	$18.38 - $40.5 $937 - $2,065	51 Added 1.65%	3,134 $114,000
Q3 2021 Nov 10, 2021	BUY	$13.18 - $19.83 $14,774 - $22,229	1,121 Added 57.14%	3,083 $53,000
Q2 2021 Aug 05, 2021	SELL	$9.59 - $50.88 $40,786 - $216,392	-4,253 Reduced 68.43%	1,962 $26,000
Q1 2021 Apr 28, 2021	SELL	$49.53 - $68.4 $16,196 - $22,366	-327 Reduced 5.0%	6,215 $318,000
Q4 2020 Feb 04, 2021	BUY	$47.25 - $65.16 $156,208 - $215,418	3,306 Added 102.16%	6,542 $405,000
Q3 2020 Nov 10, 2020	BUY	$46.35 - $61.69 $149,988 - $199,628	3,236 New	3,236 $177,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.